FDA Accelerates Psychedelic Therapy Development Following Executive Order

The U.S. Food and Drug Administration has announced a series of measures to expedite the development of psychedelic medicines targeting treatment-resistant depression, post-traumatic stress disorder (PTSD), and substance use disorders. The move follows an executive order from President Donald Trump aimed at expanding federal access to emerging health therapies. U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr. stated that the agency will prioritize treatments with 'Breakthrough Therapy' designations, focusing on those showing meaningful early improvement. This represents a strategic pivot in the federal approach to addressing the national mental health crisis through scientific acceleration. As part of the initiative, the FDA will issue national priority vouchers to firms researching psilocybin for depression and methylone for PTSD. Additionally, the agency has authorized the first-ever U.S. clinical trial for noribogaine hydrochloride, a derivative of ibogaine, as a potential treatment for alcohol use disorder. FDA Commissioner Marty Makary emphasized that while the agency is accelerating research, these drugs are not yet approved for general pharmacy prescriptions. Any future approvals will likely come with strict conditions to ensure patient safety and scientific rigor. This announcement coincides with a broader administration effort to ease restrictions on state-licensed medical cannabis operators.